Profile: Enterologics Inc (ELGO.PK)
27 Jun 2014
Enterologics, Inc., incorporated on September 2, 2009, is a biotechnology company engaged in the development of live biotherapeutic products for gastrointestinal disorders. The Company focuses to license or acquire technology to build a product pipeline based on producing probiotic bacteria in shelf-stable, formulations that are delivered orally. On September 6, 2011, the Company acquired BioBalance Corp. (BioBalance) and BioBalance LLC from New York Health Care, Inc. (NYHC). The Company acquired a probiotic product, E. coli M17.
E. coli M17 has an Investigational New Drug application (IND) with the Food & Drug Administration (United States) (FDA) for the indication of maintenance of symptomatic remission in chronic antibiotic-dependent pouchitis. As of December 31, 2011, the Company has not generated any revenues.
Suite 404, 1246 University Ave W
ST. PAUL MN 55104